{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:56:31Z","timestamp":1791590191887,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["19MC1911000"],"award-info":[{"award-number":["19MC1911000"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several studies have demonstrated that extranodal extension (ENE) is associated with prognosis in breast cancer. Whether this association should be described in pathological reports warrants further investigation. In this research, we evaluated the predictive value of ENE in axillary lymph nodes (ALNs) in invasive breast cancer and explored the feasibility of employing ENE to predict clinicopathological features, nodal burden, disease recurrence-free survival (DRFS) and overall survival (OS) in clinical practice. In addition, the cutoff values of perpendicular diameter ENE (PD-ENE) and circumferential diameter ENE (CD-ENE) of ENE were investigated. A total of 402 cases of primary invasive breast cancer were extracted from Fudan University Shanghai Cancer Center; these patients underwent axillary lymph node dissection (ALND) between 2010 and 2015. ENE in the ALN was defined as the tumor cells breaking through the lymph node capsule into peripheral adipose tissue and causing connective tissue reactions. Relationships between ENE and clinicopathological features, nodal burden, disease recurrence-free survival (DRFS) and overall survival (OS) were analyzed. PD-ENE was defined by measuring from the point where tumor tissue broke the node capsule to the highest point of the tumor cells in the perinodal adipose tissue.K The average PD-ENE was 1.8\u00a0mm; therefore, we divided ENE-positive patients into two groups: PD-ENE no greater than 2\u00a0mm and PD-ENE greater than 2\u00a0mm. CD-ENE was defined as measuring along the nodal capsule as the distance between peripheral edges of the ENE area. According to the average circumferential diameter (CD-ENE), we classified ENE-positive patients into two groups: CD-ENE no greater than 3\u00a0mm and CD-ENE greater than 3\u00a0mm. Correlations between ENE cutoffs and prognosis were analyzed. In this cohort of patients, 158 (39.3%) cases were positive for ENE in ALN.98 (24.4%) cases had PD-ENE no larger than 2\u00a0mm, and 60 (14.9%) cases had PD-ENE larger than 2\u00a0mm. Also, 112 (27.9%) cases had CD-ENE no larger than 3\u00a0mm, and 46 (11.4%) cases had CD-ENE larger than 3\u00a0mm. Statistical analysis indicated that histological grade, N stage, and HER2 overexpression subtype were associated with ENE. The presence of ENE had significant statistical correlations with nodal burden, including N stage, median metastatic tumor diameter and peri-lymph node vascular invasion (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.001, respectively). Cox regression analysis demonstrated that patients with ENE exhibited significantly reduced DRFS in both univariable analysis (HR 2.126, 95% CI 1.453\u20133.112, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and multivariable analysis (HR 1.745, 95% CI 1.152\u20132.642, <jats:italic>p<\/jats:italic>\u2009=\u20090.009) compared with patients without ENE. For overall survival (OS), patients with ENE were associated with OS in univariable analysis (HR 2.505, 95% CI 1.337\u20134.693, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) but not in multivariable analysis (HR 1.639, 95% CI 0.824\u20133.260, <jats:italic>p<\/jats:italic>\u2009=\u20090.159). Kaplan\u2013Meier curves and log-rank test showed that patients with ENE in ALN had lower DRFS and OS (for DRFS: <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001; and for OS: <jats:italic>p<\/jats:italic>\u2009=\u20090.002, respectively). However, neither the PD-ENE group (divided by 2\u00a0mm) nor the CD-ENE group (divided by 3\u00a0mm) exhibited significant differences regarding nodal burden and prognosis. Our study indicated that ENE in the ALN was a predictor of prognosis in breast cancer. ENE was an independent prognostic factor for DRFS and was associated with OS<jats:bold>.<\/jats:bold> ENE in the ALN was associated with a higher nodal burden. The size of ENE, which was classified by a 3-mm (CD-ENE) or 2-mm (PD-ENE) cutoff value, had no significant prognostic value in this study. Based on our findings, the presence of ENE should be included in routine pathological reports of breast cancers. However, the cutoff values of ENE warrant further investigation.<\/jats:p>","DOI":"10.1038\/s41598-021-88716-4","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T10:07:04Z","timestamp":1620209224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prognostic value of extranodal extension in axillary lymph node-positive breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"XiaoXi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohong","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"88716_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0002-9610(01)00719-X","volume":"182","author":"SF Abdessalam","year":"2001","unstructured":"Abdessalam, S. F. et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am. J. Surg. 182, 316\u2013320 (2001).","journal-title":"Am. J. Surg."},{"key":"88716_CR2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.breast.2005.06.010","volume":"15","author":"E Sivridis","year":"2006","unstructured":"Sivridis, E., Giatroanolaki, A., Galazios, G. & Loukourakis, M. I. Node-related factors and survival in node-positive breast carcinomas. Breast 15, 382\u2013389 (2006).","journal-title":"Breast"},{"key":"88716_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/ajcp\/65.4.439","volume":"65","author":"ER Fisher","year":"1976","unstructured":"Fisher, E. R., Gregorio, R. M., Redmond, C., Kim, W. S. & Fisher, B. Pathologic findings from national surgical adjuvant breast project (protocol no 4). 3. Significance of extranodal extension of axillary metastases. Am. J. Clin. Pathol. 65, 439\u2013444 (1976).","journal-title":"Am. J. Clin. Pathol."},{"key":"88716_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/ejso.2001.1173","volume":"27","author":"HW Palamba","year":"2001","unstructured":"Palamba, H. W., Rombouts, M. C., Ruers, T. J. M., Klinkenbijl, J. H. G. & Wobbes, T. Extranodal extension of axillary metastasis of invasive breast carcinoma as a possible predictor for the total number of positive lymph nodes. Eur. J. Surg. Oncol. 27, 719\u2013722 (2001).","journal-title":"Eur. J. Surg. Oncol."},{"key":"88716_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamasurg.2015.1687","volume":"150","author":"AH Choi","year":"2015","unstructured":"Choi, A. H. et al. Size of extranodal extension on sentinel lymph node dissection in the American College of Surgeons Oncology Group Z0011 Trial Era. JAMA Surg. 150, 1141\u20131148 (2015).","journal-title":"JAMA Surg."},{"key":"88716_CR6","first-page":"555","volume":"12","author":"S Aziz","year":"2017","unstructured":"Aziz, S. et al. Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE 12, 555 (2017).","journal-title":"PLoS ONE"},{"key":"88716_CR7","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/hed.23747","volume":"37","author":"MH Wu","year":"2015","unstructured":"Wu, M. H., Shen, W. T., Gosnell, J. & Duh, Q. Y. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Head Neck-J. Sci. Spec. 37, 1336\u20131343 (2015).","journal-title":"Head Neck-J. Sci. Spec."},{"key":"88716_CR8","first-page":"264","volume":"40","author":"JL Mu","year":"2018","unstructured":"Mu, J. L., Li, F. X., Wei, X., Xin, X. J. & Zhang, S. Clinicopathological and ultrasound characteristics of extranodal extension in metastatic papillary thyroid carcinoma patients. Zhonghua zhong liu za zhi [Chin. J. Oncol.] 40, 264\u2013267 (2018).","journal-title":"Zhonghua zhong liu za zhi [Chin. J. Oncol.]"},{"key":"88716_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jjco\/hyx055","volume":"47","author":"F Matsumoto","year":"2017","unstructured":"Matsumoto, F. et al. Prognostic significance of surgical extranodal extension in head and neck squamous cell carcinoma patients. Jpn. J. Clin. Oncol. 47, 699\u2013704 (2017).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"88716_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.juro.2013.10.140","volume":"191","author":"G Lughezzani","year":"2014","unstructured":"Lughezzani, G. et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J. Urol. 191, 977\u2013982 (2014).","journal-title":"J. Urol."},{"key":"88716_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/1008-682X.122862","volume":"16","author":"JY Wang","year":"2014","unstructured":"Wang, J. Y. et al. Prognostic significance of the degree of extranodal extension in patients with penile carcinoma. Asian J. Androl. 16, 437\u2013441 (2014).","journal-title":"Asian J. Androl."},{"key":"88716_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.juro.2011.10.158","volume":"187","author":"H Fajkovic","year":"2012","unstructured":"Fajkovic, H. et al. Prognostic Value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J. Urol. 187, 845\u2013851 (2012).","journal-title":"J. Urol."},{"key":"88716_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"Cancer J. Clin."},{"key":"88716_CR14","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.5858\/133.10.1515","volume":"133","author":"SC Lester","year":"2009","unstructured":"Lester, S. C. et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch. Pathol. Lab Med. 133, 1515\u20131538 (2009).","journal-title":"Arch. Pathol. Lab Med."},{"key":"88716_CR15","unstructured":"Patrick L.Fitzgibbons JLC, Shikha Bose, Yunn-Yi Chen, Monica E. de Baca, Mary Edgerton, Daniel F. Hayes, Kalisha A. Hill, Susan C. Lester, Jean F. Simpson, Ross Simpson, Barbara L. Smith, Lee K. Tan, Donald L. Weaver, Coll Amer, Pathologists: Protocol for the examination of resection specimens from patients with invasive carcinoma of the breast. Las Vegas February 2020."},{"key":"88716_CR16","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano, A. E., Edge, S. B. & Hortobagyi, G. N. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann. Surg Oncol. 25, 1783\u20131785 (2018).","journal-title":"Ann. Surg Oncol."},{"key":"88716_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1200\/JOP.777003","volume":"6","author":"MEH Hammond","year":"2010","unstructured":"Hammond, M. E. H., Hayes, D. F., Wolff, A. C., Mangu, P. B. & Temin, S. American society of clinical oncology\/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 6, 195\u2013197 (2010).","journal-title":"J. Oncol. Pract."},{"key":"88716_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical oncology\/college of American pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105 (2018).","journal-title":"J. Clin. Oncol."},{"key":"88716_CR19","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869\u201310874 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"88716_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"88716_CR21","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418\u20138423 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"88716_CR22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1038\/modpathol.2010.36","volume":"23","author":"DL Weaver","year":"2010","unstructured":"Weaver, D. L. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Modern Pathol. 23, S26\u2013S32 (2010).","journal-title":"Modern Pathol."},{"key":"88716_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jnci.2016.09.002","volume":"28","author":"ARH Ahmed","year":"2016","unstructured":"Ahmed, A. R. H. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer. J. Egypt. Natl. Canc. Inst. 28, 219\u2013227 (2016).","journal-title":"J. Egypt. Natl. Canc. Inst."},{"key":"88716_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/028418600750013069","volume":"39","author":"FM Hartveit","year":"2000","unstructured":"Hartveit, F. M., Lilleng, P. K. & Maehle, B. O. Efferent vascular invasion in the axillary nodes in breast carcinoma: a potent prognostic factor. Acta Oncol. 39, 309\u2013312 (2000).","journal-title":"Acta Oncol."},{"key":"88716_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/0377-4929.56123","volume":"52","author":"Z Ahmad","year":"2009","unstructured":"Ahmad, Z. et al. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and Nottingham Prognostic Index scoring on mastectomy specimens. Indian J. Pathol. Microbiol. 52, 477\u2013481 (2009).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"88716_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10147-012-0439-z","volume":"18","author":"E Dobi","year":"2013","unstructured":"Dobi, E. et al. Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?. Int. J. Clin. Oncol. 18, 607\u2013613 (2013).","journal-title":"Int. J. Clin. Oncol."},{"key":"88716_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1054\/brst.2000.0233","volume":"10","author":"JA Bucci","year":"2001","unstructured":"Bucci, J. A. et al. Implications of extranodal spread in node positive breast cancer: a review of survival and local recurrence. Breast 10, 213\u2013219 (2001).","journal-title":"Breast"},{"key":"88716_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ejso.2016.02.259","volume":"42","author":"A Nottegar","year":"2016","unstructured":"Nottegar, A. et al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Ejso-Eur. J. Surg. Oncol. 42, 919\u2013925 (2016).","journal-title":"Ejso-Eur. J. Surg. Oncol."},{"key":"88716_CR29","first-page":"3258","volume":"98","author":"DC Jiao","year":"2018","unstructured":"Jiao, D. C. et al. Analysis of factors influencing the axillary lymph node metastasis and breast cancer-specific survival in patients with T1 breast cancer. Zhonghua Yi Xue Za Zhi 98, 3258\u20133262 (2018).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"88716_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5152\/ejbh.2018.4038","volume":"14","author":"G Kanyilmaz","year":"2018","unstructured":"Kanyilmaz, G., Findik, S., Yavuz, B. B. & Aktan, M. The significance of extent of extracapsular extension in patients with T1\u20132 and N1 breast cancer. Eur. J. Breast Health 14, 218\u2013224 (2018).","journal-title":"Eur. J. Breast Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88716-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88716-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:53:21Z","timestamp":1670054001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88716-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88716"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88716-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9534"}}